Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zenocutuzumab, a bispecific antibody targeting HER2/HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Palivizumab, an antibody targeting RSV F protein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pasritamig, a bispecific antibody targeting KLK2/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Xaluritamig, a bispecific antibody targeting STEAP1/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Acapatamab, a bispecific antibody targeting PSMA/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tarlatamab, a bispecific antibody targeting DLL3/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cevostamab, a bispecific antibody targeting FcRH5/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Forimtamig, a bispecific antibody targeting GPRC5D/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Talquetamab, a bispecific antibody targeting GPRC5D/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alnuctamab, a bispecific antibody targeting BCMA/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Linvoseltamab, a bispecific antibody targeting BCMA/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Elranatamab, a bispecific antibody targeting BCMA/CD3.